This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

This study has been terminated.
(Sponsor Decision)
Information provided by (Responsible Party):
Amgen Identifier:
First received: April 1, 2010
Last updated: October 20, 2015
Last verified: October 2015
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing of AMG 827 for up to 362 weeks.

Condition Intervention Phase
Psoriasis Drug: AMG 827 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Psoriasis

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Adverse events [ Time Frame: 362 weeks ]
  • Change in laboratory parameters and vital signs [ Time Frame: 360 weeks ]

Secondary Outcome Measures:
  • The proportion of subjects with a static physician's global assessment (sPGA) of clear (0) or clear/almost clear (0 or 1) [ Time Frame: 360 weeks ]
  • Percent improvement in Psoriasis Area and Severity Index (PASI) [ Time Frame: 360 weeks ]
  • The proportion of subjects with a 50% improvement in PASI (PASI 50), PASI 75, PASI 90, and PASI 100 [ Time Frame: 360 weeks ]
  • Body surface area (BSA) involvement [ Time Frame: 360 weeks ]

Enrollment: 181
Study Start Date: April 2010
Study Completion Date: September 2015
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: AMG 827
210 mg SC or 140 mg SC


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject was randomized into Study 20090062 and completed the week 16 evaluation.

Exclusion Criteria:

  • Subject had any Serious Adverse Event (SAE) reported during Study 20090062 that was considered possibly related to IP.
  • Subject experienced an adverse event in Study 20090062 that, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01101100

United States, Georgia
Research Site
Newnan, Georgia, United States, 30263
United States, Illinois
Research Site
Skokie, Illinois, United States, 60077
United States, Missouri
Research Site
St. Louis, Missouri, United States, 63117
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States, 87106
United States, Texas
Research Site
Dallas, Texas, United States, 75246
Research Site
Webster, Texas, United States, 77598
Australia, New South Wales
Research Site
Kogarah, New South Wales, Australia, 2217
Australia, South Australia
Research Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Research Site
Parkville, Victoria, Australia, 3050
Research Site
Prahran, Victoria, Australia, 3181
Canada, Ontario
Research Site
Hamilton, Ontario, Canada, L8N 1V6
Research Site
London, Ontario, Canada, N6A 3H7
Research Site
Markham, Ontario, Canada, L3P 1A8
Research Site
Waterloo, Ontario, Canada, N2J 1C4
Research Site
Windsor, Ontario, Canada, N8W 1E6
Research Site
Quebec, Canada, G1V 4X7
Research Site
Aarhus, Denmark, 8000
Research Site
Hellerup, Denmark, 2900
Research Site
Besançon, France, 25030
Research Site
Nice, France, 06200
Research Site
Toulouse Cedex 9, France, 31059
Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT01101100     History of Changes
Other Study ID Numbers: 20090403
Study First Received: April 1, 2010
Last Updated: October 20, 2015

Keywords provided by Amgen:

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases processed this record on September 18, 2017